

ASX Announcement

10 April 2025

ReNerve Expands Global Footprint with Strategic Partnership for Indian Market

Key Highlights:

- ReNerve Limited (ASX:RNV) has formed a strategic partnership with NetCentrix Ventures to enter the high-growth Indian nerve repair market
- The Indian nerve repair sector is currently valued at US\$115M with an exceptional compound annual growth rate of 18.5%
- The Indian nerve repair market is projected to more than double to approximately US\$270M+ by year 2030
- The partnership encompasses the regulatory approval process and commercialisation strategy for the NervAlign® Nerve Cuff product

ReNerve Limited (ASX:RNV) ("**ReNerve**" or "**the Company**"), an innovative Australian medical device developer specialising in advanced peripheral nerve repair technologies, is pleased to announce a partnership agreement (the "Agreement") with NetCentrix Ventures in order to establish and develop operations in the Indian healthcare market.

Netcentrix Ventures, through its government partnerships in India, specialises in assisting Australian companies with product testing, validation and approvals to enable their products to be launched, sold and distributed into the Indian marketplace. Netcentrix Ventures has an MoU with BRIC RGCB, an institution of the Biotechnology Research and Innovation Council (BRIC) under the Department of Biotechnology, Government of India.

Strategic Partnership

The Agreement will initially focus on securing regulatory approval in the Indian market for ReNerve's flagship product, the NervAlign® Nerve Cuff. This will be followed by a coordinated commercialisation strategy that is specifically tailored to the Indian healthcare ecosystem.

This strategic collaboration grants ReNerve access to one of the fastest-growing nerve repair markets globally, with current valuations at approximately US\$115M and projected to reach US\$270M+ by the year 2030¹; representing a compound annual growth rate of 18.5%.

Market Opportunity

India represents a significant growth opportunity in peripheral nerve repair due to multiple factors, including:

- Rapidly expanding healthcare infrastructure

¹ Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)



- Increasing investment in advanced surgical capabilities for the healthcare market
- A substantial and growing middle class with improving access to specialised medical procedures
- Rising incidence of traumatic nerve injuries from industrial and transportation accidents
- Increased prevalence of diabetes-related nerve conditions requiring intervention
- Developing centres of excellence for microsurgical techniques throughout major metropolitan areas

Commenting on the partnership, Dr. Julian Chick, CEO and Managing Director of ReNerve, stated: *"India represents an exciting market opportunity in our global expansion strategy. The partnership with NetCentrix Ventures provides ReNerve with specialised local expertise and established distribution networks that are essential for a successful entry into an incredibly significant market. This Agreement complements our existing partnerships in Taiwan, Hong Kong, the Middle East, and Mexico, further strengthening our international commercialisation framework."*

"The impressive growth trajectory of India's nerve repair market aligns perfectly with our strategic vision to provide innovative nerve repair solutions to surgeons and patients worldwide. We believe the NervAlign® technology is particularly well-suited to address the specific needs of the Indian healthcare system, offering a cost-effective solution with demonstrable clinical benefits."

The NervAlign® Nerve Cuff

ReNerve's NervAlign® Nerve Cuff is designed for the protection of repaired and regenerating nerves during the healing process after peripheral nerve injuries or repair surgery. The product is unique as it protects the nerve while healing, but is also naturally absorbed within six months, leaving only regenerated and repaired tissue in the body. The medical properties of the NervAlign® Nerve Cuff mean that it is well suited for use in a wide range of nerve surgery procedures.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Jane Morgan
Investor & Media Relations
Jane Morgan Management
+61 (0) 405 555 618
info@janemorganmanagement.com.au

About ReNerve Limited

ReNerve Limited (ASX:RNV) is a medical device company specialising in advanced nerve repair and regeneration solutions. The Company is focused on commercialising cutting-edge medical devices and tissue-engineering products that seek to address significant unmet needs for patients with peripheral nerve damage – a critical gap in healthcare. ReNerve aims to improve patient outcomes through scientifically backed products that have been developed to enhance the human body's natural healing process, while commercialising cutting-edge, scalable products for the healthcare market. ReNerve wishes to acknowledge AusIndustry's Accelerating Commercialisation program for its support through many of the activities required to commercialise the NervAlign® Nerve Cuff.